These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 17919769)
1. Retreatment with pemetrexed-based chemotherapy in malignant pleural mesothelioma (MPM): a second line treatment option. Razak AR; Chatten KJ; Hughes AN Lung Cancer; 2008 May; 60(2):294-7. PubMed ID: 17919769 [TBL] [Abstract][Full Text] [Related]
2. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Ceresoli GL; Zucali PA; De Vincenzo F; Gianoncelli L; Simonelli M; Lorenzi E; Ripa C; Giordano L; Santoro A Lung Cancer; 2011 Apr; 72(1):73-7. PubMed ID: 21216487 [TBL] [Abstract][Full Text] [Related]
3. Second-line treatment for malignant pleural mesothelioma. Ceresoli GL; Zucali PA; Gianoncelli L; Lorenzi E; Santoro A Cancer Treat Rev; 2010 Feb; 36(1):24-32. PubMed ID: 19879055 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. Ceresoli GL; Zucali PA; Favaretto AG; Grossi F; Bidoli P; Del Conte G; Ceribelli A; Bearz A; Morenghi E; Cavina R; Marangolo M; Parra HJ; Santoro A J Clin Oncol; 2006 Mar; 24(9):1443-8. PubMed ID: 16549838 [TBL] [Abstract][Full Text] [Related]
5. Carboplatin and pemetrexed in the management of malignant pleural mesothelioma: a realistic treatment option? Li L; Razak AR; Hughes A Lung Cancer; 2009 May; 64(2):207-10. PubMed ID: 18926592 [TBL] [Abstract][Full Text] [Related]
6. TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed. Uramoto H; Onitsuka T; Shimokawa H; Hanagiri T Anticancer Res; 2010 Oct; 30(10):4309-15. PubMed ID: 21036757 [TBL] [Abstract][Full Text] [Related]
7. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; CollovĂ E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142 [TBL] [Abstract][Full Text] [Related]
9. Pemetrexed in malignant pleural mesothelioma. Hazarika M; White RM; Booth BP; Wang YC; Ham DY; Liang CY; Rahman A; Gobburu JV; Li N; Sridhara R; Morse DE; Lostritto R; Garvey P; Johnson JR; Pazdur R Clin Cancer Res; 2005 Feb; 11(3):982-92. PubMed ID: 15709163 [TBL] [Abstract][Full Text] [Related]
10. Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany. Reck M; Stahel RA; von Pawel J; Karthaus M; Korfee S; Serke M; Schuette WH; Eschbach C; Fink TH; Leschinger MI; Manegold C Respir Med; 2010 Jan; 104(1):142-8. PubMed ID: 19818589 [TBL] [Abstract][Full Text] [Related]
11. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Katirtzoglou N; Gkiozos I; Makrilia N; Tsaroucha E; Rapti A; Stratakos G; Fountzilas G; Syrigos KN Clin Lung Cancer; 2010 Jan; 11(1):30-5. PubMed ID: 20085865 [TBL] [Abstract][Full Text] [Related]
12. Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed. Hayashi H; Okamoto I; Ichikawa Y; Miyazaki M; Yoshioka H; Kunimasa K; Nakagawa K Int J Clin Oncol; 2010 Oct; 15(5):497-9. PubMed ID: 20224880 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881 [TBL] [Abstract][Full Text] [Related]
15. A retrospective study of chemotherapy with and without pemetrexed in malignant pleural mesothelioma. Higashiguchi M; Suzuki H; Hirashima T; Kobayashi M; Goya S; Okamoto N; Matsuura Y; Tamiya M; Morishita N; Tsumori T; Kawase I Anticancer Res; 2012 Feb; 32(2):609-13. PubMed ID: 22287752 [TBL] [Abstract][Full Text] [Related]
16. Life after first-line chemotherapy in malignant pleural mesothelioma: a North-East England experience. Steer J; Bough G; Razak AR; Meachery GJ; Hughes A Clin Oncol (R Coll Radiol); 2010 Apr; 22(3):231-5. PubMed ID: 20346340 [TBL] [Abstract][Full Text] [Related]
17. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma]. Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136 [TBL] [Abstract][Full Text] [Related]
18. [Update of pemetrexed in thoracic oncology]. Brechot JM; Morère JF Bull Cancer; 2007; 94 Spec No Actualites():S139-41. PubMed ID: 17845984 [TBL] [Abstract][Full Text] [Related]
19. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. Jassem J; Ramlau R; Santoro A; Schuette W; Chemaissani A; Hong S; Blatter J; Adachi S; Hanauske A; Manegold C J Clin Oncol; 2008 Apr; 26(10):1698-704. PubMed ID: 18375898 [TBL] [Abstract][Full Text] [Related]
20. [First-line treatment with pemetrexed in association with cisplatin in patients with non-operable malignant pleural mesothelioma]. Burgin M; Gairard-Dory A-; Mennecier B; Molard A; Beretz L; Quoix A- Rev Pneumol Clin; 2009 Apr; 65(2):75-83. PubMed ID: 19375046 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]